PierianDx

Deal Snapshot

Company: PierianDx, Inc. now Velsera

Website: pieriandx.com

Sector / Category: Clinical genomics software and knowledge base / precision medicine reporting and workflow for next-generation sequencing (NGS)

Headquarters: St. Louis, Missouri, USA

Founded: 2014

Investor: Frazier VC

Investment Vehicle: Fund III

Deal Type: Primary + Secondary

Company Overview

PierianDx provides software, services, and a curated clinical genomics knowledge base that help labs and healthcare organizations interpret genomic data and produce concise, clinically actionable reports. The company’s platform is designed to streamline NGS testing workflows, support interpretation at scale, and enable health systems to deliver precision medicine programs locally with faster turnaround and greater control over quality.

Public Funding / Capital Events

Jan 7, 2016 — Series A financing announcedPierianDx announced it closed a Series A financing led by Health Catalyst Capital Management.

Oct 28, 2019 — $27M Series B raisedPierian announced a $27M Series B led by ATW Partners and SJF Ventures, with participation from existing investors including Health Catalyst Capital, Inova Health System, RTI International, and ARUP Laboratories.

Nov 2, 2021 — $30M growth capital (with access to additional tranches up to $17.5M)Pierian announced it closed $30M of new growth capital including equity financing and a term loan facility, with access to additional tranches up to $17.5M in 2022 and 2023 subject to conditions.

Jan 2023 — Pierian becomes part of Velsera (Summa Equity acquisition/merger)Summa Equity acquired and combined Pierian, Seven Bridges, and UgenTec to form Velsera.

Investment Summary

Frazier VC invested in PierianDx through both primary and secondary purchases in June 2021. This investment activity reflects conviction in PierianDx’s workflow-embedded role in clinical genomics, where software, knowledge base depth, and operational integration can scale as more organizations internalize precision medicine programs.

Why We Invested

Frazier VC invested in PierianDx because we look for scalable, mission-critical software that becomes embedded in complex clinical workflows. PierianDx supports interpretation and reporting at the point where genomic data becomes clinical decision support, with defensibility strengthened through curated knowledge, integration depth, and high switching costs once standardized across lab and health system processes. We also value strong leadership teams operating in regulated environments where execution, quality, and reliability are essential.

Other Investors

ATW Partners

SJF Ventures

Health Catalyst Capital

Inova Health System

RTI International

ARUP Laboratories

OrbiMed